Journal of the Chinese Medical Association : JCMA · 2003
The long-term results of one time treatment by continuously fractionated transpupillary thermotherapy for occult choroid neovascularization membrane of age-related macular degeneration.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Shu-Fang, Lin Po-Kang, Liu Jorn-Hon
Аннотация
BACKGROUND: This study was to assess the long-term results of a novel continuously fractionated transpupillary thermotherapy (cfTTT) in treating occult choroid neovascularization membrane (CNV) of age-related macular degeneration (ARMD).
METHODS: After informed consent was obtained, 19 patients were treated with cfTTT in 21 eyes. The diode laser (810 nm) was applied with 6 continuous 9-second sessions to the neovascular membrane. Each session lasted 9 seconds. Every spot (1 mm on retina) was in close contact with each other to entirely cover the CNV.
RESULTS: The average age was 75.9 years (from 61 to 86 years). The mean follow-up time was 19.6 months (from 15 to 24 months). Five eyes (23.8%) had improved visual acuity by 2 or more lines, 6 eyes (28.5%) by 1 line, and 10 eyes (47.6%) had no change in visual acuity. None had decreased vision. In final fluorescein angiography, all eyes treated revealed decreased fluorescein leakage.
CONCLUSIONS: cfTTT shows no deleterious side effects in treating subfoveal or juxtafoveal CNV of ARMD at long-term follow-up and is at least as effective as long-pulse TTT.
METHODS: After informed consent was obtained, 19 patients were treated with cfTTT in 21 eyes. The diode laser (810 nm) was applied with 6 continuous 9-second sessions to the neovascular membrane. Each session lasted 9 seconds. Every spot (1 mm on retina) was in close contact with each other to entirely cover the CNV.
RESULTS: The average age was 75.9 years (from 61 to 86 years). The mean follow-up time was 19.6 months (from 15 to 24 months). Five eyes (23.8%) had improved visual acuity by 2 or more lines, 6 eyes (28.5%) by 1 line, and 10 eyes (47.6%) had no change in visual acuity. None had decreased vision. In final fluorescein angiography, all eyes treated revealed decreased fluorescein leakage.
CONCLUSIONS: cfTTT shows no deleterious side effects in treating subfoveal or juxtafoveal CNV of ARMD at long-term follow-up and is at least as effective as long-pulse TTT.